REG - SSE Plc - Scrip Alternative

SSEAnnouncement

29/08/2024 12:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240829:nRSc1788Ca&default-theme=true

RNS Number : 1788C  SSE PLC  29 August 2024

SSE PLC

FINAL DIVIDEND FOR THE YEAR ENDED 31 MARCH 2024

SCRIP ALTERNATIVE

SSE plc was notified on 28 August 2024 that a total of 24,277 shareholders
have elected to receive the final dividend for the year ended 31 March 2024 of
40 pence per ordinary share in respect of 563,868,396 ordinary shares in the
form of Scrip dividend.  This will result in a reduction in final dividend
cash funding of £225,547,358.

A total of 12,203,570 new ordinary shares, fully paid, will be issued on 19
September 2024, representing an increase of 1.12% on the issued share capital
(excluding treasury shares) on the dividend record date of 26 July 2024.  The
relevant Scrip Reference Share Price was 1,848 pence per ordinary share.

The Group's dividend plan to 2026/27 includes the intention to cap the scrip
dividend alternative at 25% of investor uptake, through a share buy-back where
required. Following notification of the final dividend elections, the Group
can confirm that overall scrip dividend take-up for the financial year ended
31 March 2024 was 35.7%. In accordance with the authority granted by
shareholders at SSE's Annual General Meeting on 18 July 2024 and Chapter 12 of
the Listing Rules, the Group therefore intends to initiate a share buy-back in
the period following the final dividend payment for the year ended 31 March
2024.  The number of ordinary shares to be purchased will not exceed
3,806,487 ordinary shares, and the maximum pecuniary amount allocated to the
Scrip buy-back is £75,000,000.  SSE plc intends to complete this process by
31 March 2025.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DIVFLFVITVIAFIS